Valuation: CSPC Pharmaceutical Group Limited

Market Cap 99.35B 12.66B 10.94B 10.3B 9.36B 17.56B 1,208B 17.88B 120B 47.14B 606B 47.54B 46.5B 2,018B P/E 2026 *
11.7x
P/E 2027 * 14.4x
Enterprise Value 89.01B 11.34B 9.8B 9.22B 8.38B 15.73B 1,082B 16.02B 108B 42.23B 543B 42.59B 41.66B 1,807B EV / Sales 2026 *
2.46x
EV / Sales 2027 * 2.46x
Free-Float
67.42%
Yield 2026 *
4.57%
Yield 2027 * 4.2%
Aug. 11 CSPC Pharma Starts Phase 1 Trial of CAR-T Drug for Relapsed, Refractory Lupus MT
Aug. 10 CSPC Pharmaceutical's Mpox Vaccine Candidate Gets Trial Approval from US FDA MT
Aug. 05 CSPC Pharma Gets $10 Million Milestone Payment from AstraZeneca Under Research Deal MT
Aug. 05 CSPC Pharma, AstraZeneca Form JV to Build Biologics Manufacturing Facility in China MT
Aug. 05 CSPC Pharmaceutical Group Limited Announces Receipt of USD 10 Million Milestone Payment Under the Strategic Research Collaboration Agreement with Astrazeneca CI
Aug. 05 CSPC Pharmaceutical Group Limited And AstraZeneca Enter Into Joint Venture Contract For Establishment Of Joint Venture To Further Deepen Strategic Collaboration CI
Aug. 04 CSPC Pharma Unit, Alphamab Oncology's Breast Cancer Drug Application Granted Priority Review in China MT
Aug. 04 CSPC Pharmaceutical Group Limited New Drug Application For Anbenitamab And Docetaxel For Injection (Albumin-Bound) For Neoadjuvant Treatment Accepted By The NMPA CI
Aug. 03 CSPC Pharma Begins Phase Ib/II Trial of Colorectal Cancer Drug Candidate MT
Aug. 03 CSPC Pharmaceutical Group Limited Initiates Phase Ib/II Clinical Trial Of SYS6090 Injection For Treatment Of Colorectal Cancer CI
Aug. 02 CSPC Pharma Wins China Trial Approval for RSV Vaccine MT
Jul. 31 CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial Of SYS6041 as Combination Therapy for Treatment of Recurrent Ovarian Cancer At First Centre in China CI
Jul. 31 CSPC Pharmaceutical Group Limited Announces Recombinant Respiratory Syncytial Virus Vaccine SYS6057 Obtains Clinical Trial Approval In China CI
1 day-1.81%
1 week+2.24%
Current month+1.28%
1 month+6.50%
3 months+7.95%
6 months-14.05%
Current year+3.08%
1 week 8.52
Extreme 8.52
9.22
1 month 7.97
Extreme 7.97
9.22
Current year 6.53
Extreme 6.53
10.96
1 year 6.53
Extreme 6.53
11.63
3 years 4.27
Extreme 4.27
11.63
5 years 4.27
Extreme 4.27
11.9
10 years 3.61
Extreme 3.609374
13.93
Manager TitleAgeSince
Chief Executive Officer 46 2025-12-18
Chief Operating Officer 56 2025-12-18
Corporate Officer/Principal 44 2024-06-30
Director TitleAgeSince
Chairman 72 2011-08-25
Director/Board Member 56 2012-01-19
Director/Board Member 66 2012-12-20
Date Insider Type Main position Quantity % Market Cap.
6/23/26 Other

Director

-700,000 0.0061%
12/23/25 Other

Chairman

6,706,000 0.0582%
11/25/25 Other

Chairman

10,300,000 0.0894%
Change 5-day change 1-year change 3-year change Capi.($)
-1.81%+2.24%-18.94%+50.61% 12.89B
-2.25%-0.99%+78.68%+123.40% 1,078B
-0.66%+1.31%+49.27%+49.76% 632B
-0.54%+2.29%+23.82%+63.92% 443B
-1.99%-2.63%+42.21%+33.92% 356B
-1.05%-2.19%+25.55%+34.88% 289B
-2.12%-3.29%+0.14%+3.90% 245B
-0.63%+2.56%+43.51%+58.17% 226B
-1.19%+0.37%-9.57%-52.51% 204B
+0.16%+5.73%+15.17%+72.95% 171B
Average -0.87%+1.70%+24.98%+43.90% 365.66B
Weighted average by Cap. -0.36%+1.31%+43.52%+63.30%

Financials

2026 *2027 *
Net sales 36.14B 4.61B 3.98B 3.75B 3.4B 6.39B 439B 6.5B 43.84B 17.15B 220B 17.29B 16.92B 734B 35.13B 4.48B 3.87B 3.64B 3.31B 6.21B 427B 6.32B 42.6B 16.66B 214B 16.81B 16.44B 713B
Net income 8.29B 1.06B 914M 860M 781M 1.47B 101B 1.49B 10.06B 3.93B 50.59B 3.97B 3.88B 168B 6.84B 872M 754M 709M 645M 1.21B 83.21B 1.23B 8.3B 3.25B 41.75B 3.27B 3.2B 139B
Net Debt -10.34B -1.32B -1.14B -1.07B -974M -1.83B -126B -1.86B -12.54B -4.91B -63.09B -4.95B -4.84B -210B -13.09B -1.67B -1.44B -1.36B -1.23B -2.31B -159B -2.36B -15.87B -6.21B -79.84B -6.26B -6.13B -266B
Logo CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.
Employees
19,700
Date Price Change Volume
26-08-14 HK$8.690 -1.81% 39,418,434
26-08-13 HK$8.850 +2.02% 105,733,552
26-08-12 HK$8.675 -0.29% 50,923,111
26-08-11 HK$8.700 +0.87% 72,200,336
26-08-10 HK$8.625 -0.75% 86,457,309
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
8.690HKD
Average target price
11.72HKD
Spread / Average Target
+34.85%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 1093 Stock